Search research articles
Contact Us
Filters
Showing results (31-40 of 54) with videos related to
Page
of 6
Sort By:
Hepatology Communications
|
August 16, 2022
Development and validation of the Cirrhotic Ascites Severity model-A patient-reported outcome-based model to predict 1-year mortality
Rasmus Hvidbjerg Gantzel, Niels Kristian Aagaard, Hendrik Vilstrup, et al.
Gut
|
August 13, 2011
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
Florence Wong, Hugh Watson, Alexander Gerbes, et al.
The Lancet. Infectious Diseases
|
May 22, 2021
What chikungunya teaches us about COVID-19
Fabrice Simon, Hugh Watson, Jean-Baptiste Meynard, et al.
Hepatology Communications
|
June 27, 2024
Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites
Rasmus H Gantzel, Emilie E Møller, Niels K Aagaard, et al.
Journal of Hepatology
|
June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
Florence Wong, Pere Gines, Hugh Watson, et al.
World Journal of Hepatology
|
June 1, 2022
Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
Rasmus Hvidbjerg Gantzel, Mikkel Breinholt Kjær, Peter Jepsen, et al.
Danish Medical Journal
|
December 1, 2021
Ularitide as treatment of refractory ascites in cirrhosis- a study protocol for a randomised trial
Rasmus Hvidbjerg Gantzel, Markus Meyer, Stefan Mazgareanu, et al.
Journal of Hepatology
|
July 25, 2012
Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema
Elsa Solà, Hugh Watson, Isabel Graupera, et al.
Clinical Rheumatology
|
January 10, 2020
Stiffness, pain, and joint counts in chronic chikungunya disease: relevance to disability and quality of life
Hugh Watson, Sarah R Tritsch, Liliana Encinales, et al.
Antiviral Research
|
March 27, 2022
Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease
Justin G Julander, Nicole Anderson, Nicole Haese, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 54) with videos related to
Sort By:
Page
of 6
Hepatology Communications
|
August 16, 2022
Development and validation of the Cirrhotic Ascites Severity model-A patient-reported outcome-based model to predict 1-year mortality
Rasmus Hvidbjerg Gantzel, Niels Kristian Aagaard, Hendrik Vilstrup, et al.
Gut
|
August 13, 2011
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
Florence Wong, Hugh Watson, Alexander Gerbes, et al.
The Lancet. Infectious Diseases
|
May 22, 2021
What chikungunya teaches us about COVID-19
Fabrice Simon, Hugh Watson, Jean-Baptiste Meynard, et al.
Hepatology Communications
|
June 27, 2024
Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites
Rasmus H Gantzel, Emilie E Møller, Niels K Aagaard, et al.
Journal of Hepatology
|
June 15, 2010
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis
Florence Wong, Pere Gines, Hugh Watson, et al.
World Journal of Hepatology
|
June 1, 2022
Effects and safety of natriuretic peptides as treatment of cirrhotic ascites: A systematic review and meta-analysis
Rasmus Hvidbjerg Gantzel, Mikkel Breinholt Kjær, Peter Jepsen, et al.
Danish Medical Journal
|
December 1, 2021
Ularitide as treatment of refractory ascites in cirrhosis- a study protocol for a randomised trial
Rasmus Hvidbjerg Gantzel, Markus Meyer, Stefan Mazgareanu, et al.
Journal of Hepatology
|
July 25, 2012
Factors related to quality of life in patients with cirrhosis and ascites: relevance of serum sodium concentration and leg edema
Elsa Solà, Hugh Watson, Isabel Graupera, et al.
Clinical Rheumatology
|
January 10, 2020
Stiffness, pain, and joint counts in chronic chikungunya disease: relevance to disability and quality of life
Hugh Watson, Sarah R Tritsch, Liliana Encinales, et al.
Antiviral Research
|
March 27, 2022
Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease
Justin G Julander, Nicole Anderson, Nicole Haese, et al.
Page
of 6